<DOC>
	<DOCNO>NCT02176161</DOCNO>
	<brief_summary>This Phase II clinical study determine Metformin increase Prostate Specific Antigen ( PSA ) double time patient Prostate Cancer fail primary treatment radiation , surgical patient high risk recurrence base surgical pathology . Men confirm prostate cancer rise serum PSA level receive Metformin monitor PSA response disease progression .</brief_summary>
	<brief_title>Metformin Prostate Cancer Adjuvant Trial</brief_title>
	<detailed_description>Prostate cancer patient receive treatment radiation therapy surgery , indicator high-risk disease administer 750mg Metformin Extended Release twice per day period 9 month . Metformin FDA-approved drug prescribe treat high blood sugar level patient Type 2 Diabetes . To track prostate cancer response study participant , investigator obtain prostate specific antigen ( PSA ) level every three month duration trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male &gt; 18 year age Biopsy confirm adenocarcinoma prostate Able swallow retain oral medication Hemoglobin A1C &lt; 7.0 % Able willing participate full 12 month study Able understand instruction relate study procedure Able read write English Metastatic Prostate Cancer Prostate Specific Antigen Doubling Time &lt; 6 month Prior Chemotherapy , hormonal therapy , oral glucocorticoid therapy , Gonadotropinreleasing hormone analogue therapy Current previous use 5Î±reductase inhibitor , antiandrogen drug , metformin , oral injectable diabetes drug Diagnosis Type 1 Diabetes Mellitus Known hypersensitivity metformin condition associate increase risk metformin associate lactic acidosis participation investigational market drug trial within 30 day prior screen study period unstable , serious coexist medical condition include limited myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior screen history megaloblastic anemia abnormal liver function test ( total bilirubin , aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase serum creatinine upper limit normal ) history malignancy , exception adequately treat nonmelanoma skin cancer , stage 1 melanoma , nonmuscle invasive bladder cancer , solid tumor curatively treat evidence disease least 5 year history current evidence substance abuse within 12 month screen history illness ( include psychiatric ) , opinion investigator , might confound result study post additional risk subject</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Cancer Recurrent</keyword>
</DOC>